Rate My Professor Rachel Gibson

Professor Gibson's research specializations center on supportive care in cancer, with a particular emphasis on mucositis secondary to cancer therapy, pathobiology of treatment-induced gastrointestinal damage, chemotherapy-induced diarrhoea and constipation, and related mechanisms. She has made substantial contributions to the field through leadership roles in the Multinational Association of Supportive Care in Cancer (MASCC), including significant involvement in its activities over many years. In 2019, she received the MASCC Distinguished Service Award in recognition of her contributions to supportive care in cancer. Her scholarly impact is evidenced by highly cited publications, including co-authorship of the MASCC/ISOO clinical practice guidelines for mucositis management (Cancer, 2020), 'Emerging evidence on the pathobiology of mucositis' (Supportive Care in Cancer, 2013), 'Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies' (Supportive Care in Cancer, 2006), 'Systematic review of agents for the management of gastrointestinal mucositis in cancer patients' (Supportive Care in Cancer, 2013), and 'VSL#3 probiotic treatment reduces chemotherapy-induced diarrhoea and weight loss' (Cancer Biology & Therapy, 2007). These works have advanced understanding and clinical guidelines in oncology supportive care.